Interleukin-6 May Contribute to Mortality in Parkinson's Disease Patients: A 4-Year Prospective Study

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00085127" target="_blank" >RIV/00216224:14110/15:00085127 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00159816:_____/15:00063976

Výsledek na webu

<a href="http://dx.doi.org/10.1155/2015/898192" target="_blank" >http://dx.doi.org/10.1155/2015/898192</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1155/2015/898192" target="_blank" >10.1155/2015/898192</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Interleukin-6 May Contribute to Mortality in Parkinson's Disease Patients: A 4-Year Prospective Study

Popis výsledku v původním jazyce

Objectives. The association between abnormal serum immunomarkers and mortality in 53 consecutive Parkinson's disease patients was studied. Materials and Methods. The plasma level of specific inflammatory cytokines was investigated: mannan-binding lectin(MBL), interleukin-(IL-) 6, and tumor necrosis factor-alpha (TNF-alpha). The baseline serum immunomarkers obtained from patients who died (n = 16) during a four-year follow-up period were compared with the data of patients who survived (n = 37). Results.The baseline level of IL-6 was significantly higher in the deceased patients than in the survivors. Elevated IL-6 levels and age were major independent contributors to disease mortality. Differences between other plasma cytokine level abnormalities werenot significant. Conclusion. This study showed that IL-6 elevation may be a marker of increased mortality risk in Parkinson's disease patients.

Název v anglickém jazyce

Interleukin-6 May Contribute to Mortality in Parkinson's Disease Patients: A 4-Year Prospective Study

Popis výsledku anglicky

Objectives. The association between abnormal serum immunomarkers and mortality in 53 consecutive Parkinson's disease patients was studied. Materials and Methods. The plasma level of specific inflammatory cytokines was investigated: mannan-binding lectin(MBL), interleukin-(IL-) 6, and tumor necrosis factor-alpha (TNF-alpha). The baseline serum immunomarkers obtained from patients who died (n = 16) during a four-year follow-up period were compared with the data of patients who survived (n = 37). Results.The baseline level of IL-6 was significantly higher in the deceased patients than in the survivors. Elevated IL-6 levels and age were major independent contributors to disease mortality. Differences between other plasma cytokine level abnormalities werenot significant. Conclusion. This study showed that IL-6 elevation may be a marker of increased mortality risk in Parkinson's disease patients.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/ED1.1.00%2F02.0068" target="_blank" >ED1.1.00/02.0068: CEITEC - central european institute of technology</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Parkinsons Disease

ISSN

2090-8083

e-ISSN

—

Svazek periodika

2015

Číslo periodika v rámci svazku

898192

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

1-5

Kód UT WoS článku

000360499700001

EID výsledku v databázi Scopus

—